Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in adults ≥18 years of age and the elderly.
The use of Prevenar 13 should be determined on the basis of official recommendations taking into consideration the impact of invasive disease in different age groups as well as the variability of serotype epidemiology in different geographical areas.
Prevenar 13 may be administered with the seasonal trivalent influenza vaccine and quadrivalent inactivated influenza vaccine (QIV) in people aged 50 years and older.
Burden of disease in adults and the elderly
Pneumonia is the most common clinical presentation of pneumococcal disease in adults.
The reported incidence of community-acquired pneumonia (CAP) and IPD in Europe varies by country, increases with age from 50 years and is highest in individuals aged ≥ 65 years. S. pneumoniae is the most frequent cause of CAP, and is estimated to be responsible for approximately 30% of all CAP cases requiring hospitalisation in adults in developed countries.
Bacteraemic pneumonia (approximately 80% of IPD in adults), bacteraemia without a focus, and meningitis are the most common manifestations of IPD in adults.
In a literature review published in 2018 looking at the burden of pneumococcal CAP in adults across Europe, it was found that most cases (30%–78%) were caused by serotypes covered by Prevenar 13 and the incidence of Prevenar 13-related pneumonia decreased after the introduction of childhood vaccination.
The risk for CAP and IPD in adults also increases with chronic underlying medical conditions, specifically, anatomical or functional asplenia, diabetes mellitus, asthma, chronic cardiovascular, pulmonary, kidney or liver disease, and it is highest in those who are immune-suppressed such as those with malignant haematological diseases or HIV infection.